FiercePharma2h
Syndax ⁠scores FDA approval for Revuforj after it disappointed in another acute leukemia indication
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
FiercePharma2h
With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum for Dialogue'
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
FiercePharma2h
VBI Vaccines recalls hepatitis B shot as it winds down operations
Months after filing for bankruptcy, VBI Vaccines is taking the next step in shuttering operations with the voluntarily ...
FiercePharma6h
Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...
FiercePharma8h
Cleanup for the IL-23 class in ulcerative colitis as new drugs 'rapidly gained significant momentum': report
The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...
FiercePharma3h
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...